BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells

Clicks: 262
ID: 273840
2004
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Prostate cancer is one of the most common cancers in men. Several lines of evidence have suggested that bone morphogenetic protein (BMP) signals play important roles in the generation and progression of prostate cancers. In the present study, we show that BMP-7 inhibits the proliferation of androgen …
Reference Key
h2004oncogenebmp Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Miyazaki H;Watabe T;Kitamura T;Miyazono K;;
Journal Oncogene
Year 2004
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/15531927
Keywords
Tumor National Center for Biotechnology Information NCBI NLM MEDLINE Mice animals pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't male signal transduction* cell line Inbred BALB C Receptors cell proliferation* reverse transcriptase polymerase chain reaction phosphorylation up-regulation tetracycline / pharmacology androgens / physiology* transforming growth factor beta / metabolism bone morphogenetic protein receptors type i bone morphogenetic proteins / physiology* protein-serine-threonine kinases / genetics growth factor / genetics cell cycle proteins / metabolism prostatic neoplasms / pathology* cyclin-dependent kinase 2 cyclin-dependent kinase inhibitor p21 bone morphogenetic protein 7 pmid:15531927 doi:10.1038/sj.onc.1208127 hideyo miyazaki tetsuro watabe kohei miyazono bone morphogenetic proteins / metabolism cdc2-cdc28 kinases / antagonists & inhibitors immunoprecipitation retinoblastoma protein / metabolism transforming growth factor beta / physiology*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.